Colorectal Cancer Clinical Trial
Official title:
B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA
RATIONALE: Diagnostic procedures using boronophenylalanine-fructose complex (BPA-F) and/or
sodium borocaptate (BSH) to detect the presence of boron in tumor cells may help determine
whether patients who have thyroid cancer, head and neck cancer, or liver metastases may
benefit from boron neutron capture therapy.
PURPOSE: This phase I trial is studying the side effects of giving BPA-F and/or BSH before
surgery to detect boron uptake in tissues of patients with primary, metastatic, or recurrent
thyroid cancer, head and neck cancer, or liver metastases from colorectal cancer.
OBJECTIVES:
- Identify additional solid tumors that may benefit from boron neutron capture therapy.
- Determine the boron concentration in the tumor, surrounding tissues, and blood of
patients with operable thyroid cancer, squamous cell cancer of the head and neck, or
liver metastases secondary to colorectal adenocarcinoma who receive
boronophenylalanine-fructose complex (BPA-F) and/or sodium borocaptate (BSH) before
surgical resection.
- Determine the feasibility of using these drugs to obtain a favorable absolute boron-10
concentration in the tumor and optimal tumor-to-blood and tumor-to-healthy tissue
boron-10 rates in these patients.
- Determine the qualitative and quantitative toxicity of combined BPA-F and BSH
administration in these patients.
OUTLINE: This is a multicenter study. Patients are sequentially assigned to 1 of 3 treatment
groups.
- Group I: Patients receive boronophenylalanine-fructose complex (BPA-F) IV over 1 hour.
Two hours later, patients undergo surgical resection.
- Group II: Patients receive sodium borocaptate (BSH) IV over 1 hour. Twelve hours later,
patients undergo surgical resection.
- Group III: Patients receive BSH IV over 1 hour (administered 12 hours prior to surgery)
and BPA-F IV over 1 hour (administered 2 hours prior to surgery). Patients then undergo
surgical resection.
During the planned surgery, tissue samples from the tumor and surrounding tissues are
collected.
Patients are followed on days 1 and 5 and then at 4 weeks.
PROJECTED ACCRUAL: A maximum of 27 patients will be accrued for this study.
;
Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |